Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated With Tyro3 Receptor Upregulation.
CNPase
MBP
PeaLut
TAM receptors
oligodendrocyte progenitor cells
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
04
2021
accepted:
15
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Remyelination in patients with multiple sclerosis frequently fails, especially in the chronic phase of the disease promoting axonal and neuronal degeneration and progressive disease disability. Drug-based therapies able to promote endogenous remyelination capability of oligodendrocytes are thus emerging as primary approaches to multiple sclerosis. We have recently reported that the co-ultramicronized composite of palmitoylethanolamide and the flavonoid luteolin (PEALut) promotes oligodendrocyte precursor cell (OPC) maturation without affecting proliferation. Since TAM receptor signaling has been reported to be important modulator of oligodendrocyte survival
Identifiants
pubmed: 34276381
doi: 10.3389/fphar.2021.698133
pii: 698133
pmc: PMC8277943
doi:
Types de publication
Journal Article
Langues
eng
Pagination
698133Informations de copyright
Copyright © 2021 Facci, Barbierato, Fusco, Giusti and Zusso.
Déclaration de conflit d'intérêts
MF was employed by the company Epitech Group SpA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurochem. 2004 Sep;90(5):1173-85
pubmed: 15312172
Mol Neurobiol. 2018 Jan;55(1):103-114
pubmed: 28822061
J Mol Neurosci. 2018 Aug;65(4):491-506
pubmed: 30083786
Front Neurol. 2017 Jun 06;8:233
pubmed: 28634464
Neuropathol Appl Neurobiol. 2007 Jun;33(3):277-87
pubmed: 17442065
J Neurosci Res. 2006 Aug 15;84(3):534-41
pubmed: 16773649
Expert Opin Ther Targets. 2009 Dec;13(12):1375-86
pubmed: 19839715
J Neurotrauma. 2016 Jan 1;33(1):132-46
pubmed: 25046306
Rev Neurol (Paris). 2016 Jan;172(1):3-13
pubmed: 26718593
Mol Biol Cell. 2015 Oct 1;26(19):3489-503
pubmed: 26224309
PLoS One. 2011 Mar 10;6(3):e17727
pubmed: 21423702
J Neurosci Res. 1988 Oct-Dec;21(2-4):249-59
pubmed: 2464077
J Neuroinflammation. 2011 May 15;8:49
pubmed: 21569627
Glia. 2017 Dec;65(12):2051-2069
pubmed: 28925029
ASN Neuro. 2016 Sep 14;8(5):
pubmed: 27630207
J Neurosci. 2009 May 13;29(19):6367-78
pubmed: 19439614
Glia. 2017 Apr;65(4):581-591
pubmed: 28145605
J Cell Sci. 2014 Jul 15;127(Pt 14):2999-3004
pubmed: 25024457
J Neurosci. 2014 Mar 26;34(13):4453-65
pubmed: 24671992
Neurosignals. 2009;17(4):277-87
pubmed: 19816064
Neuron. 2018 Feb 21;97(4):742-768
pubmed: 29470968
Sci Rep. 2015 Nov 18;5:16676
pubmed: 26578323
Transl Stroke Res. 2016 Feb;7(1):54-69
pubmed: 26706245
Physiol Rev. 2001 Apr;81(2):871-927
pubmed: 11274346
Br J Pharmacol. 2017 Jun;174(11):1349-1365
pubmed: 27539936
J Neuroinflammation. 2019 Jun 20;16(1):126
pubmed: 31221190
ASN Neuro. 2014 Jan 24;6(1):e00135
pubmed: 24476104
Br J Pharmacol. 2011 Aug;163(7):1520-32
pubmed: 21480865
Front Pharmacol. 2016 Mar 08;7:47
pubmed: 27014061
Nat Rev Neurosci. 2008 Nov;9(11):839-55
pubmed: 18931697
Biochem Soc Trans. 2013 Aug;41(4):944-50
pubmed: 23863161
Nat Rev Neurosci. 2017 Nov 16;18(12):753-769
pubmed: 29142295
Dev Neurosci. 1990;12(4-5):251-62
pubmed: 1963138
Methods Mol Biol. 2012;846:67-77
pubmed: 22367802
J Neurosci Res. 1981;6(3):369-80
pubmed: 6170762
Brain Res. 2014 Jan 13;1542:206-20
pubmed: 24184575
J Comp Neurol. 2000 Sep 18;425(2):295-314
pubmed: 10954847